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The calculation and comparison of relative survival rates 
after interventional studies is a method that permits cor- 
rection for important demographic variables, thereby ad- 
justing for the “background mortality” in the general 
population. Long-term relative survival rates were ana- 
lyzed in a consecutive series of 2,805 Swedish patients who, 
on the basis of clinical symptoms, underwent aortic valve 
replacement (n = 1,741), mitral valve replacement (n = 
792) and double (aortic plus mitral) valve replacement (n = 
272) between 1969 and 1983. The follow-up period, which 
closed August 1, 1985, included 100% of patients and 
covered 16,822 patient-years. Autopsy was performed in 
75% of all deaths. 
The results underscore previously well known differ- 
ences between the long-term survival after aortic valve 
replacement and mitral or double valve replacement, 
whereas no differences were noted between mitral and 
double valve replacement. Within the subgroup undergoing 
aortic valve replacement, analysis of relative survival rates 
Long-term results after prosthetic heart valve replacement 
are usually presented in actuarial terms (1,2). Risk factors 
for premature death have been identified by further analyz- 
ing these actuarial curves by univariate or multivariate 
methods (3-10). By these means, the prospects for patients 
undergoing valve replacement are fairly well established. 
This provides an opportunity to preoperatively identify high 
risk patients and to undertake special precautions in selected 
cases (5). These analyses, however, do not usually relate the 
observed survival of the surgically treated patients to the 
expected survival as experienced in the general population. 
The relative survival rate is defined as the ratio of the 
observed survival in a group of patients during a specified 
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disclosed a highly significant (p < 0.001) difference between 
patients operated on for aortic stenosis and those operated 
on for aortic regurgitation, representing a mortality rate 
more than twice as high in the latter group. This difference 
was of much lesser magnitude when analyzed in the stan- 
dard (actuarial) way. With a low (<2.5%) operative mor- 
tality rate for patients undergoing isolated elective aortic 
valve replacement in the current era and with an acceptable 
incidence of late valve-related death (5.2% at 10 years), 
these results may justify aortic valve replacement earlier in 
the course of chronic aortic regurgitation to prevent irre- 
versible myocardial damage. 
Patients ~65 years of age who underwent aortic valve 
replacement for pure aortic stenosis achieved a normalized 
survival pattern from the second postoperative year on, and 
had a “cure” rate of 94%, which, however, is partly 
related to preoperative patient selection. 
(J Am Coil Cardiol1990;15:566-73) 
time interval to the survival expected from the general 
population experience (11). The relative survival rate can be 
considered to represent a measure of escaping the extra risk 
of dying from the disease under study (12). In this way, it can 
also be used to estimate the proportion of patients “cured” 
by the treatment (12,13). 
The relative survival rate has been widely used when 
analyzing patient survival after treatment for cancer (13,14), 
but to our knowledge, no analyses of relative survival rates 
after valve replacement have been reported. The present 
study was undertaken to further elucidate the long-term 
prospect for patients undergoing aortic or mitral valve re- 
placement, or both. 
The aims of this study were 1) to present and compare the 
relative survival rates for various subgroups of patients 
undergoing valve replacement, 2) to study whether any 
subgroup of patients experienced a “normalized” survival 
pattern after valve replacement (that is, ‘if any fraction of 
these patients could be considered “cured” from a statistical 
point of view), and 3) to assess the magnitude of the 
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Table 1. Clinical Characteristics of 2,805 Patients 
All AVR MVR DVR 
(n = 2,805) (tl = 1,741) (n = 792) (n = 212) 
Age (yr) 
Mean 56.7 57.3 55.7 55.9 
Range lo-80 1 l-80 IO-79 Id-76 
Gender (% male) 57 67 38 49 
Emergency procedure (%) 3.6 4.5 1.8 2.7 
Previous heart (%) surgery 11.3 2.7 29.0 14.3 
Concomitant procedure (%) 16.1 15.8 20.4 18.0 
Hemodynamic lesion (%) 
Stenosis 4x.5 23.1 - 
Mixed - 28.7 38.6 
Insufficiency - 22.8 38.3 - 
Early mortality rate (%) 5.6 5.4 5.4 7.0 
(95CL) (4.7-6.4) (4.3-6.5) (3.8-7.1) (3.X-10.2) 
AVR = aortic valve replacement; DVR = double (aortic and mitral) valve replacement; MVR = mitral valve 
replacement; 95CL = 95% confidence limits. 
increased “intercurrent mortality” among these patients and 
whether it could be linked to prosthesis-related factors or to 
an increased number of deaths from myocardial causes. 
Methods 
Study patients. Between January 1969 and July 1983, 
2,884 patients underwent aortic or mitral valve replacement, 
or both, at this institution. Fifty-six foreign patients who 
stayed in Sweden for only a short period after the operation 
were excluded because expected survival was calculated on 
the basis of Swedish inhabitants (see later). Furthermore, 23 
children and teenagers who underwent valve replacement as 
part of the treatment for complex congenital malformations 
were excluded. The remaining 2,805 patients formed the 
basis of this study. There were 1,741 aortic valve replace- 
ments, 792 mitral valve replacements and 272 double (aortic 
plus mitral) valve replacements. Some patient characteris- 
tics are listed in Table 1, and the age distribution is illus- 
trated in Figure 1. 
Operative and postoperative management. Standard car- 
diopulmonary bypass equipment and moderate perfusion 
hypothermia (25” to 32°C) were employed. Cardioplegia was 
routinely used since 1978. All but one patient received 
Bjork-Shiley tilting disc valves (15,16). All valves were 
implanted with interrupted sutures. Reheparinization was 
started as soon as the chest tubes were removed. Oral 
anticoagulants with an intention of life-long treatment and 
Thrombotest (Thrombotest, Nyegaard, Oslo, Norway) val- 
ues between 6% and 15% were prescribed for all patients 
undergoing mitral or double valve replacement and for most 
patients after aortic valve replacement (8,16). All survivors 
received antibiotic prophylaxis for 2 to 3 months postoper- 
atively. 
Follow-up and data collection. Our methods of data col- 
lection have been outlined previously (8,15-17). Follow-up 
study was achieved by means of telephone calls or postal 
questionnaires, or both. All patients were followed up to 
August 1, 1985. The follow-up study was 100% and covered 
16,822 patient-years. The mean follow-up time was 6.4 years 
for operative (30 days) survivors and 7.1 years (range 2.1 to 
16.6) for current survivors. Fifty-four percent of the patients 
were followed up >5 years, 18% >lO years and 2% >15 
years. 
Assignment of cause of death. Cause of death was as- 
signed according to autopsy reports, which were available in 
638 (75%) of 856 deaths. In cases lacking an autopsy, we 
scrutinized hospital records in search for valve-related com- 
plications. 
Figure 1. Age distribution among 2,805 patients undergoing aortic 
or mitral valve replacement, or both, between January I%9 and 
June 1983. 
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Figure 2. Observed survival (O[s]) among 2,805 patients 
undergoing aortic or mitral valve replacement, or both. 
The expected survival rate (E[s]) line represents the 
experienced survival in a gender- age- and year of 
operation-matched control group. The vertical bar indi- 
cates the 95% confidence limits (95CL). PAT = patient; 
POST-OP = postoperatively. 
Valve-related death. The following causes of death were 
considered valve-related: embolism, valve thrombosis, anti- 
coagulant-related hemorrhage, mechanical failure, pros- 
thetic valve endocarditis and noninfectious periprosthetic 
leakage (15,16). All fatal strokes were considered either as 
embolism or as anticoagulant-related bleeding, and thus in 
all cases were regarded as valve-related death. Any death 
occurring during or within 30 days of a reoperation for a 
valve-related complication was considered valve related. 
Cardiac but not valve-related death. Patients who died 
from congestive heart failure without signs of prosthetic 
malfunction, patients who died from myocardial infarction 
without evidence of embolism and patients who died from 
documented arrhythmias were considered to have died a 
cardiac but not valve-related death. 
Sudden unexplained death. Patients unexpectedly found 
dead, patients who died suddenly within a matter of minutes 
and patients who died within 48 h after the sudden onset of 
symptoms compatible with severe left ventricular failure but 
without an autopsy were considered to have died a sudden 
unexplained death. (The probability that sudden unexplained 
deaths are caused by valve-related complications was ex- 
plored in a previous study [17].) 
Other causes of death. All other causes of death (for 
example, trauma, cancer, infection) were grouped together 
as “other.” 
Statistical methods. Actuarial curves describing observed 
survival (O[s]) and freedom from valve-related death were 
constructed and compared using standard formulas 
(2,18,19). 
The expected survival (E[s]) was calculated in an “exact” 
way (II) from Swedish life tables with a specially designed 
computer software program.* Briefly, this program assigns a 
*Further details of this program are available from the authors. 
separate “control group” for every patient in the study 
group. This control group consists of all Swedish inhabitants 
of the same gender and age as the patient and alive at the 
time of operation. The expected survival for this control 
group was then retrieved from computer-based life tables 
(“Statistics Sweden”) that cover the entire Swedish popu- 
lation (because >50% of our patients were referred from 
outside Stockholm, we used life tables for Sweden rather 
than for Stockholm only). All these individually based ex- 
pected survival curves were then weighted to a composite 
survival curve that represented all patients (Fig. 2). Because 
of the age heterogeneity in the patient cohort (Fig. l), a 
successive rejuvenation process due to a higher mortality 
rate among older patients may be present (14). To correct for 
this and to avoid overestimating the relative survival rate, 
the control groups that represented patients who died during 
the follow-up period were withdrawn from the calculations 
of E(s) at the year of the respective patient’s death. Because 
the calculations of E(s) are based on the entire Swedish 
population, the errors of sampling do not apply and no 
standard errors are provided for E(s). The relative survival 
rate is calculated as O(s)/E(s). 
Presentation and interpretation of relative survival rates. 
The relative survival rates are calculated with successively 
longer time intervals, all of which start at the time of 
operation. If the study group eventually achieves a normal- 
ized survival pattern, this is represented by a constant 
relative survival rate from that time on. The fraction surviv- 
ing until this normalized survival is reached is, therefore, 
subject only to the normal risk of dying and can be consid- 
ered as “cured” from a statistical point of view. If, on the 
other hand, there is an increased risk of death in the study 
group throughout the study period, this will be represented 
by a continuously decreasing relative survival rate. 
In studies of survival after treatment for cancer, relative 
survival rates are sometimes compared with the actuarial 
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Figure 3. Causes of death (early and late) MECHANICAL FAIL. (I. 9%) 
among 856 patients. Highlighted sectors repre- OTHER CARDIAC 
sent valve-related deaths. ANTICOAG. = an- 
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survival in the study group, but with all noncancer deaths 
regarded as withdrawals (13). Both types of survival analysis 
represent methods to correct for intercurrent disease. If the 
relative survival rate is lower than this cancer survival rate, 
this can be interpreted as an increased incidence of intercur- 
rent disease in the study group. When considering survival 
after valve replacement, these patients are exposed to a 
number of new potential causes of death, such as prosthetic 
dysfunction, thromboembolism and anticoagulant-related 
bleeding. Our patients can, therefore, be considered to have 
traded acquired valvular disease for prosthetic valvular 
disease (9), the risks of which are not negligible. In analogy 
with cancer survival and to assess the incidence of intercur- 
rent disease among patients with artificial heart valves, we 
compared the relative survival rates with the actuarial free- 
dom from valve-related death. 
Illustrations of actuarial or relative survival are graphi- 
cally presented with logarithmic y axis because this facili- 
tates a visual comparison between different curves (that is. 
subgroups with equal hazard rate during a specified time 
interval have parallel survival curves). Actuarial and relative 
Table 2. Incidence of Valve-Related Mortality in 2,805 Patients 
survival rates as well as binomial proportions are presented 
together with their 95% confidence limits. 
Results 
Overall survival. Of the 2,805 patients operated on, 156 
(5.6%, 95% confidence limits 4.7% to 6.4%) died within 30 
days of surgery and 700 (25%) died later during the follow-up 
period. An autopsy was performed in 638 (75%) of these 
deaths. One hundred fifty-six (18%, 95% confidence limits 
16% to 21%) of these deaths were considered valve related 
(Fig. 3). The incidence of valve-related death among various 
subgroups of patients is illustrated and compared in Table 2. 
The actuarial survival for all patients was 77%, 63% and 48% 
at 5. 10 and 15 years after operation. respectively (Fig. 2). 
Ten year actuarial survival rate was significantly higher 
among patients who underwent aortic valve replacement 
(66%, 95% confidence limits 63% to 69%) than among those 
undergoing mitral or double valve replacement (58%, 95% 
confidence limits 54% to 63%, and 57%, 95% confidence 
limits 50% to 65%, respectively). Furthermore, patients 
Procedure 
Linearized Rate 
(events/100 
patient years) 
Actuarial incidence (%I 
5 Years 10 Years 
Significance at 
10 Years 
All (n = 2,805) 0.9 -c cl.1 5.3 (4.4-6.2) 7.4 (6.2-8.6) 
AVR 
All (n = 1,741) 0.7 2 0.1 3.7 (2.X-4.6) 5.7 
(4.3-7.2) 
- For AS 845) t 4 1-4.7) 
(3.5-7.X) 
For AI (n = 397) 0.8 2 0.2 4.3 (2.1-6.51 5.2 (2.7-7.7) 1 NS 1 p < 0.01 
MVR 
AII (n = 792) 1.3 + 0.2 X.2 (6.1-10.3) 10.1 (7.5-12.7) p < 0.05 
For MS (n = 183) 1.2 ? 0.3 7.9 (3.6-12. I) 8.8 (4.2-13.3) 
For MI (n = 303) 1.4 _f 0.3 7.7 f4.4-10.9) 9.9 (5.4-14.5) 1 NS NS 
DVR (n = 272) 1.3 + 0.3 7.2 (3.6-10.7) 9.9 (5.3-14.6) 1 
Data in parentheses represent 95% confidence limits. AI = aortic insufficiency: AS = aortic stenosis; MI = mitral insufficiency: MS = mitral stenosis; other 
abbreviations as in Table 1. 
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Table 3. Actuarial Survival at 10 Years in 2.805 Patients 100 
Procedure Survival (%) 
AVR 
AU (n = 1,741) 65.8 (62.8-68.8) 
For AS (n = 845) 68.3 (63.8-72.8) 
For AI (n = 397) 59.4 (53.6-65.2) 
MVR 
All (n = 792) 58.2 (53.8-62.6) 
For MS (n = 183) 65.4 (56.1-74.7) 
For MI (n = 303) 53.1 (45.9-60.3) 
DVR (n = 272) 57.3 (49.8-64.8) 
Data in parentheses represent 95% confidence limits. Abbreviations as in 
Tables 1 and 2. 
undergoing aortic or mitral valve replacement for pure 
regurgitant lesions had a significantly increased mortality 
rate than patients operated on because of pure stenotic 
lesions (Table 3). 
Relative survival. When calculating relative survival, the 
differences among some of the subgroups became even more 
pronounced. The relative survival rate did not differ between 
patients undergoing mitral or double valve replacement, but 
in both patient groups the rate was significantly (p < 0.01) 
lower than that for patients undergoing aortic valve replace- 
ment (Fig. 4). This increased mortality rate among patients 
with mitral or double valve replacement persisted through- 
out the follow-up period. 
Figure 4. Relative survival rates among patients undergoing aortic 
(AVR) (solid line, n = 1741), mitral (MVR) (dashed line, n = 792) and 
double (DVR), (dash-dot line, n = 272) valve replacement. Note 
different truncation of the y axis in this and subsequent figures. 
Vertical bars indicate 95% confidence limits. POST-OP = postoper- 
atively. 
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Figure 5. Relative survival rates for patients operated on for pure 
aortic stenosis (AS, n = 845) or pure aortic insufkiency (AI, R = 
397). Vertical bars indicate 95% confidence limits. POST-OP = 
postoperatively. 
The relative survival rate in patients with aortic regurgi- 
tation was significantly (p < 0.001, Fig. 5) lower than in 
patients with aortic stenosis and represented a more than 
doubled mortality rate. This increased mortality rate was 
observed (Fig. 5) until the fifth postoperative year, after 
which time the relative survival curves became parallel. 
The lower survival rate among patients undergoing mitral 
valve replacement for pure mitral insujiciency was con- 
firmed but not enhanced when analyzed as relative survival 
rates (Fig. 6). The relative (and also actuarial) survival 
curves ran parallel from the second postoperative year. 
Because early mortality did not differ between these groups 
of patients, this increased mortality was only present during 
postoperative months 2 to 12. 
Patients aged 265 years who underwent aortic valve 
replacement for dominating aortic stenosis constituted the 
only group that obtained a normalized survival pattern after 
operation. This was reached after the first postoperative year 
and was accompanied by a “cure” rate of 94% (95% 
confidence limits 91% to 97%) (Fig. 7). 
The relative survival rate was significantly lower than the 
actuarial freedom from valve-related death among patients 
undergoing aortic, mitral or double valve replacement 
(Fig. 8). 
Time-frame analysis (Table 4). Because a major change in 
surgical treatment was introduced in 1978 (that is, the 
routine use of cardioplegia), relative survival analyses were 
performed with patients being stratified according to time 
frame (patients operated on during 1969 to 1977 versus 
patients operated on during 1978 to 1983). The only statisti- 
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Figure 6. Relative survival rates for patients undergoing valve Figure 8. Actuarial freedom from valve-related mortality and rela- 
replacement for pure mitral stenosis (MS, n = 183) or pure mitral tive survival rates among patients undergoing aortic (AVR) or mitral 
insufficiency (MI, n = 303). Vertical bars indicate 95% confidence (MVR) valve replacement. Vertical bars indicate 95% confidence 
limits. POST-OP = postoperatively. limits. POST-OP = postoperatively. 
tally significant difference found was an improved survival 
rate in the latter era for patients undergoing aortic valve 
replacement. This difference was of much lesser magnitude 
when only patients ~65 years old were considered. No time 
Figure 7. Relative survival rates for patients operated on for pure 
aortic stenosis (AS). Patients are stratified according to age; AS 
265 = 65 to 80 years and AS ~65 = 11 to 64 years. Fewer than 30 
patients 265 years remained for analysis beyond postoperative year 
9. Vertical bars indicate 95% confidence limits. POST-OP = post- 
operatively. 
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frame-dependent differences were noted for patients under- 
going mitral or double valve replacement. 
Discussion 
Limitations of the present study. Two major arguments 
have been raised against the appropriateness of comparing 
postoperative survival with survival in a general population 
(20). The first is that calculations of expected survival are 
based on the unverified assumption that the survival in the 
Table 4. Relative Survival Rates at 5 Years According to Time 
Frame (1969 to 1977 versus 1978 to 1983) 
Procedure 
Relative 
Survival (%) Significance 
AVR 
Early (n = 778) 
Late In = 963) 
83.9 (80.9-87.0) 
89.9 (86.9-92.9) 
p < 0.01 
AVR 165 yr 
Early (n = 675) 84.1 (80.9-87.2) 
Late (n = 583) 88.2 (84.7-91.6) 
p i 0.05 
MVR 
Early (n = 397) 75.3 (70.7-79.9) 
Late (n = 395) 79.6 (74.5-84.5) 
NS 
DVR 
Early (n = 125) 74.9 (66.5-83.2) 
Late (n = 147) 75.4 (66.8-84.1) 
NS 
Data in parentheses represent 95% confidence limits. Abbreviations as in 
Tables 1 and 2. 
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general population is unaffected by deaths related to the 
disease under study. This argument may be relevant in 
studies of ischemic heart disease, but because of its relative 
rarity, valvular heart disease influences survival in the 
general population only marginally. The second argument is 
that the populations may not be matched socioeconomically. 
This argument seems less valid in Sweden where the avail- 
ability of surgical treatment is mainly unrelated to socioeco- 
nomic factors. 
Experiences from the present study. Valve replacement is 
the treatment of choice for most significant valve lesions. 
Hemodynamic improvement has been documented by sev- 
eral postoperative catheterization studies (21-23), especially 
in patients undergoing surgery for stenotic lesions. In com- 
parison with historic series (24,25), the superiority over 
medical treatment seems firmly established. This is espe- 
cially true for patients with aortic stenosis, for which a 50% 
mortality rate within 2 years after the onset of symptoms has 
been reported with medical treatment alone (24). Yet, the 
present study has clearly demonstrated the inability to 
“cure” these patients, except in the subgroup of old (265 
years) patients undergoing aortic valve replacement for pure 
aortic stenosis. Even this concept of “cure” can be disputed 
because these older patients represent a selected group, with 
an underrepresentation of other serious disorders that are 
otherwise common in this age group (26). It must neverthe- 
less be considered gratifying to observe a 94% “cure” rate 
and a normalized survival pattern in this group of patients 
whose disease has a very serious outcome without surgery. 
The identical relative survival rate after mitral and double 
valve replacement (Fig. 4) implies that the longer cross- 
clamp time and the presence of two prostheses did not affect 
the late results adversely. 
The finding in all patient groups that the relative survival 
rate was much lower than the actuarial freedom from valve- 
related death (Fig. 8) indicates that the inability to achieve a 
“cured” group was not primarily linked to the incidence of 
valve-related complications, but rather to the incidence of 
“intercurrent disease.” Because the fraction of noncardiac 
deaths was low (17%) (Fig. 3), this increased incidence of 
intercurrent disease was mainly related to a high incidence of 
deaths attributable to myocardial factors. 
Future improvements. Further improvements in survival 
after valve replacement may be achieved in at least three 
different ways: 1) by improved surgical treatment (defined 
broadly, including overall perioperative management); 2) by 
improved prosthetic heart valves; and 3) by improved pre- 
operative myocardial function (that is, a changed referral 
pattern). 
So-called improvements in the surgical treatment are 
constantly introduced, but their effects on long-term survival 
are seldom documented. Ferrazzi et al. (5) recently studied 
the long-term survival after mitral valve replacement during 
two different time frames. Contrary to current beliefs, they 
found that results analyzed in a multivariate fashion re- 
mained unchanged during the latter era. This is corroborated 
by our findings of small or nonexisting differences when 
relative survival was analyzed in relation to time frame 
(Table 4). The only improvement observed in the most 
recent era was among patients undergoing aortic valve 
replacement. This was, however, mainly related to an in- 
creased number of old patients having aortic valve replace- 
ment (39% were 265 years in the latter era compared with 
13% before 1978). With a normalized relative survival rate 
among patients in this age group (Fig. 7), a higher relative 
survival rate must be expected in the entire aortic valve 
replacement group after 1977. 
New heart valves are also introduced, each of which is 
assigned various advantages in terms of improved hemody- 
namic performance or decreased incidence of valve-related 
complications. Only long-term follow-up studies can prove 
whether one valve is superior to another, and in the absence 
of well controlled randomized trials, comparisons among 
different prostheses can, at best, only be guiding. Even if 
further improvements in the design of prosthetic valves are 
likely, the chance that this will more than marginally im- 
prove long-term survival seems small. 
The third possibility for achieving improved results would 
be to operate on patients in a less advanced state of the 
disease. The patients in this series were all accepted for 
valve replacement on the basis of symptoms. The poor 
results obtained among patients with aortic regurgitation as 
compared with patients with aortic stenosis are well known 
from several previous studies (6,7,10) which, however, did 
not correct for major variations in demographic variables. 
Despite an equal incidence of valve-related death (Table 2), 
patients with aortic regurgitation had a more than doubled 
mortality rate when relative survival rates were considered 
(Fig. 5). Several authors (27-29) have claimed that asymp- 
tomatic patients with severe aortic regurgitation should be 
recommended for surgery on the basis of noninvasively 
detected signs of left ventricular dysfunction. Concerned by 
the high incidence of sudden unexpected death among 
asymptomatic patients with depressed left ventricular func- 
tion and encouraged by the low operative mortality rate and 
improved long-term survival rate among patients operated 
on early in the course of chronic aortic regurgitation, Turina 
et al. (30) currently recommend surgery even in the absence 
of symptoms in patients with signs of depressed left ventric- 
ular function. With a current early mortality rate in the range 
of 1% to 2.5% (8,16,30) for patients undergoing isolated 
elective aortic valve replacement, and with a yearly inci- 
dence of late valve-related death of 0.7 + 0.1% (actuarially 
3.7% at 5 years and 5.7% at 10 years, Table 2) (16), it would 
probably be justified to operate on patients with chronic 
aortic regurgitation earlier to lower the late mortality rate. 
Mitral valve replacement carries a significantly higher early 
mortality rate and an almost doubled incidence of late 
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valve-related death (Table 2) (9,10,15), and more liberal 
indications for this procedure seem less warranted. 
Conclusions 
1. Most subgroups of patients did not achieve a normal- 
ized survival pattern after valve replacement, a finding that 
illustrates the palliative rather than the curative effect of 
surgery. The increased mortality rate after valve replace- 
ment seems mainly linked to an increased number of cardiac 
but not valve-related deaths. 2. This increased late mortality 
rate was especially marked among patients operated on 
because of aortic regurgitation and among patients undergo- 
ing mitral or double valve replacement. 3. Patients aged 265 
years who underwent valve replacement for aortic stenosis 
can, from a statistical point of view, be considered “cured” 
if they survive the first postoperative year. 4. Our data 
support the idea of earlier referral to surgery for patients 
with chronic aortic regurgitation. 5. Analysis of relative 
survival rates provide a meaningful way to compare results 
among different patient groups. It takes into account varia- 
tions in important demographic variables, thereby correcting 
for the “background” mortality. 
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